Company Filing History:
Years Active: 1995-2000
Title: Reiko Namikawa: Innovator in Hematopoietic Research
Introduction
Reiko Namikawa is a prominent inventor based in Palo Alto, California. She has made significant contributions to the field of hematopoietic research, holding a total of seven patents. Her work focuses on innovative methods to enhance human hematopoiesis and develop experimental models for cancer research.
Latest Patents
One of her latest patents is titled "Extended human hematopoiesis in a heterologous host." This invention provides a functional human hematopoietic system within an immunocompromised mammalian host, allowing for extended periods of hematopoietic function. The method involves introducing human fetal liver tissue and human fetal thymus into a young immunocompromised mouse, resulting in the formation of functional human bone marrow tissue. Another notable patent is the "Small animal metastasis model," which outlines a method for initiating metastasis of human tumor cells under experimental conditions. This model utilizes immunocompromised non-human mammals with viable xenogeneic organs or tissues as hosts for human tumor cells, enabling the evaluation of therapeutic regimens against metastatic processes.
Career Highlights
Reiko Namikawa is currently employed at Systemix, Inc., where she continues her groundbreaking research. Her work has garnered attention in the scientific community, contributing to advancements in both hematopoietic systems and cancer treatment methodologies.
Collaborations
Throughout her career, Namikawa has collaborated with notable colleagues, including Joseph M McCune and Hideto Kaneshima. These partnerships have further enriched her research and expanded the impact of her innovations.
Conclusion
Reiko Namikawa's contributions to hematopoietic research and cancer modeling are invaluable. Her innovative patents and collaborative efforts continue to push the boundaries of scientific understanding and application.